ClinicalTrials.gg
CompletedNCT02017015PANC-001Updated Sep 26, 2017Results posted

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

A Phase 2 interventional study of nab-paclitaxel and Gemcitabine in Pancreatic Neoplasms, sponsored by Celgene. Completed at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-26.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Enrollment
40th of 130
83 · median 47
Started
2013
with 6 others
Phase 2
69 of 130
14 open now
Registered
16th of 130
by date
Lead sponsor
8 of 130
Celgene

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 40th largest by enrollment, is one of 7 that started in 2013, is one of 69 in phase 2, and was the 16th registered.

Pancreatic Neoplasms

3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel combined with gemcitabine in Chinese patients with metastatic pancreatic cancer.

Read the detailed description

This is a Phase 2 trial in China to evaluate the safety and efficacy of the combination of nab-paclitaxel and gemcitabine administered in patients diagnosed with metastatic pancreatic adenocarcinoma. This study is designed to be a Chinese bridging study to complement the Global pivotal study (CA-046).

The study consists of three parts: (1) Dose evaluation; (2) Single arm to evaluate efficacy following an optimal Simon two-stage design; and (3) Randomized 2-arm to evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine versus gemcitabine alone. These 3 parts will be carried out sequentially. The Part 3 randomized 2-arm portion will only be carried out if deemed necessary per protocol.

03

Conditions studied

  • Pancreatic Neoplasms

Keywords

  • Pancreatic cancer
  • Metastatic pancreatic cancer
  • treatment for pancreatic cancer
  • Abraxane clinical research trials
  • Celgene clinical research trials
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has definitive or cytologically confirmed pancreatic adenocarcinoma (Islet cell neoplasms are excluded) that is measurable by Response Evaluation criteria for solid tumors ( V1.0)
  2. Patients must have received no previous radiotherapy, surgery, chemotherapy or therapy for the treatment of metastatic pancreatic cancer. Prior treatment with 5-fluorouracil (5-FU) or gemcitabine administered as a radiation sensitizer in the setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. Patients having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study
  3. Patient has a performance status (KPS) ≥ 70
  4. Initial diagnosis of metastatic disease must have occurred ≤ 6 weeks prior to starting Cycle 1 Day 1. NOTE: the clock for this time interval starts with the date of last evaluation confirming pancreatic metastatic disease (either or imaging results)
  5. Patients should be asymptomatic for jaundice prior to Cycle 1 Day 1. Significant or symptomatic amounts of ascites should be drained prior to Cycle 1 Day 1. Pain symptoms should be stable and should not require modifications in analgesic management prior to Cycle 1 Day 1
  6. Patient has adequate blood counts at screening (obtained ≤ 14 days prior to starting Cycle 1 Day 1):

    • (ANC) ≥ 1.5 × 10\^9/L;
    • count ≥ 100,000/mm\^3 (100 × 10\^9/L);
    • (Hgb) ≥ 9 g/dL
  7. Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to starting Cycle 1 Day 1):

    • (SGOT) and alanine transaminase (SGPT) are ≤ 2.5 (ULN) range, unless liver metastases are clearly present, then ≤ 5 × upper limit of normal (ULN) range is allowed
    • Total ≤ upper limit of normal range
    • Serum creatinine within normal limits or calculated clearance ≥ 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above or below the institutional normal value. If using , actual body weight should be used for calculating creatinine clearance (eg, using the Cockcroft-Gault formula). For patients with a (BMI) > 30 kg/m\^2, lean body weight should be used instead.
  8. The patient has acceptable coagulation studies (obtained ≤14 days prior to starting Cycle 1 Day 1) as demonstrated by (PT) and partial thromboplastin time (PTT) within normal limits (WNL) ±15%.
  9. The patient has no abnormalities in urinalysis results (obtained ≤14 days prior to starting Cycle 1 Day 1).
  10. Male or non-pregnant and non-lactating female, and ≥ 18 years of age at the time of signing the document.

    • If a female patient is of , as evidenced by regular menstrual periods, she must have a negative pregnancy test (e.g. serum β-subunit of human chorionic gonadotropin (β-hCG) documented prior to the first administration of study drug.
    • If sexually active, the patient must agree to use considered adequate and appropriate by the Investigator during the period of administration of study drug. In addition, male and female patients must utilize contraception after the end of treatment as recommended in the product's
  11. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study-related activities.
  12. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Patient has known
  2. Patient has only locally advanced disease.
  3. Patient has a ≥ 20% decrease in serum albumin level between Screening visit and within 72 hours prior to Cycle 1 Day 1.
  4. History of in the last 5 years (including chronic leukemias). Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.
  5. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  6. Patient has known infection with , and/or active infection with , or (patients with known historical infection with hepatitis B or C should be discussed with the Sponsor).
  7. Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
  8. Patient that has a history of a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, (NYHA) Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or (ECG) abnormality, cerebrovascular accident, , seizure disorder or clinically significant cardiac dysrhythmia or ECG abnormality, within 6 months prior to Cycle 1 Day 1
  9. Patient has a history of allergy or to any of the study drugs or any of their , or the patient exhibits any of the adverse events .
  10. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).
  11. Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.
  12. Patient has any condition, including serious medical risk factors, medical conditions, laboratory abnormalities or psychiatric disorders, which could compromise the patient's safety or the study data integrity.
  13. Patient is enrolled in any other clinical protocol or trial with an interventional agent or assessments that may interfere with study procedures.
  14. Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the treatment phase of the study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    nab-paclitaxel with gemcitabine

    nab-paclitaxel at 125 mg/m\^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).

    Drug: nab-paclitaxel · Drug: Gemcitabine

Interventions

  • nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)

    Also known as: ABI-007, Abraxane

  • Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Based on Independent Radiological Review (IRR)

    ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) based on independent radiological review per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (V1.0). Using RECIST Version 1.0, participants were to achieve either a complete response defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the independent radiological review of best overall response during study treatment.

    Time frame: Assessment every 8 weeks; Day 1 to data cut off of 01 June 2015; Up to approximately 70 weeks

Secondary outcomes

  1. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)

    TEAEs were defined as adverse events (AEs) that began or worsened in severity on or after the date of the first dose of study drug and within 30 days of the last dose of study drug. A Serious AE (SAE) = any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, is a congenital anomaly/birth defect; constitutes an important medical event. Treatment-related AEs (TRAEs) were any TEAEs considered to be related to the study drug. A TRAE is a TEAE with relationship as suspected to either ABI-007 or gemcitabine The intensity of AEs were graded 1 to 5 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Other AEs not described in the CTCAE criteria, the intensity will be assessed by the investigator as mild grade (Gr 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5)

    Time frame: Study drug initiation through 30 days after the last dose of study drug or End Of Study, whichever is later; maximum treatment duration was 54.9 weeks

  2. Duration of Response (DoR) Based on IRR According to RECIST Guidelines

    DoR was defined as the time from the first tumor assessment when the confirmed CR/PR response criterion is met to the date of disease progression based on IRR following RECIST 1.0. Only for those participants with a confirmed CR/PR. If a participant had disease progression, then the date of disease progression was the event date. For a participant who did not develop disease progression or disease progression occurred after 2 or more missing tumor assessments, the participant was censored on the date of last tumor assessment where the participant was documented to be progression free. If a participant died prior to disease progression, the participant was censored on the date of death. If patient started new anti-cancer therapy, the patient was censored on the last tumor assessment date on or prior to the start date of new anti-cancer therapy

    Time frame: Assessment performed every 8 weeks; from the first participant enrolled to cut off date of 01 June 2015; up to approximately 70 weeks

  3. Kaplan-Meier Estimate of Overall Survival (OS)

    Overall survival was defined as the time from the date of first treatment to the date of death. Participants who did not die at the end of study or clinical data cut were censored on the last-known-to-be-alive date or the clinical cut-off date, whichever was earlier.

    Time frame: From the first participant enrolled to data cut off of 01 June 2015; up to approximately 70 weeks

07

Results

Posted Nov 22, 2016

Participant flow

This multi-center study was conducted by investigators in China and enrolled patients at a total of 13 sites. This study was designed to be a Chinese bridging study to complement the global pivotal study (CA046).

Participant flow — Overall Study
MilestoneNab-paclitaxel and Gemcitabine
Started83
Safety population83
Completed14
Not completed69
Withdrew: Adverse event9
Withdrew: Withdrawal by subject21
Withdrew: Death4
Withdrew: Progressive disease31
Withdrew: Non-compliance with study drug2
Withdrew: Physician decision2

Outcome measures

SecondaryNumber of Participants Experiencing Treatment Emergent Adverse Events (TEAE)

TEAEs were defined as adverse events (AEs) that began or worsened in severity on or after the date of the first dose of study drug and within 30 days of the last dose of study drug. A Serious AE (SAE) = any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, is a congenital anomaly/birth defect; constitutes an important medical event. Treatment-related AEs (TRAEs) were any TEAEs considered to be related to the study drug. A TRAE is a TEAE with relationship as suspected to either ABI-007 or gemcitabine The intensity of AEs were graded 1 to 5 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Other AEs not described in the CTCAE criteria, the intensity will be assessed by the investigator as mild grade (Gr 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5)

Time frame:
Study drug initiation through 30 days after the last dose of study drug or End Of Study, whichever is later; maximum treatment duration was 54.9 weeks
Reported as:
Number · participants
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)
participantsNab-paclitaxel and Gemcitabine
At least 1 TEAE83
At Least 1 Treatment-related TEAE82
≥ 1 TEAE with NCI CTCAE Gr 3 or higher70
≥ 1 TRAE NCI CTCAE ≥ Gr 362
At Least 1 Serious TEAE20
At Least 1 Treatment-related Serious TEAE9
≥ 1 TEAE causing discontinuing of either drug10
≥1 TRAE causing discontinuing of either drug5
≥ 1 TEAE causing reduction in ABI-007/Gemcitabine38
≥ 1 TRAE causing reduction in ABI-007/Gemcitabine38
≥1 TEAE causing interruption in either study drug43
≥1 TRAE causing interruption in either study drug40
At Least 1 TEAE With Outcome of Death8
≥1 TRAE with Outcome of Death2
PrimaryOverall Response Rate (ORR) Based on Independent Radiological Review (IRR)

ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) based on independent radiological review per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (V1.0). Using RECIST Version 1.0, participants were to achieve either a complete response defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the independent radiological review of best overall response during study treatment.

Time frame:
Assessment every 8 weeks; Day 1 to data cut off of 01 June 2015; Up to approximately 70 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Based on Independent Radiological Review (IRR)
percentage of participantsNab-paclitaxel and Gemcitabine
Overall Response Rate (ORR) Based on Independent Radiological Review (IRR)35 (24.8 to 46.2)
SecondaryDuration of Response (DoR) Based on IRR According to RECIST Guidelines

DoR was defined as the time from the first tumor assessment when the confirmed CR/PR response criterion is met to the date of disease progression based on IRR following RECIST 1.0. Only for those participants with a confirmed CR/PR. If a participant had disease progression, then the date of disease progression was the event date. For a participant who did not develop disease progression or disease progression occurred after 2 or more missing tumor assessments, the participant was censored on the date of last tumor assessment where the participant was documented to be progression free. If a participant died prior to disease progression, the participant was censored on the date of death. If patient started new anti-cancer therapy, the patient was censored on the last tumor assessment date on or prior to the start date of new anti-cancer therapy

Time frame:
Assessment performed every 8 weeks; from the first participant enrolled to cut off date of 01 June 2015; up to approximately 70 weeks
Reported as:
Median · months
Duration of Response (DoR) Based on IRR According to RECIST Guidelines
monthsNab-paclitaxel With Gemcitabine
Duration of Response (DoR) Based on IRR According to RECIST Guidelines8.9 (6.01 to 8.94)
SecondaryKaplan-Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time from the date of first treatment to the date of death. Participants who did not die at the end of study or clinical data cut were censored on the last-known-to-be-alive date or the clinical cut-off date, whichever was earlier.

Time frame:
From the first participant enrolled to data cut off of 01 June 2015; up to approximately 70 weeks
Reported as:
Median · months
Kaplan-Meier Estimate of Overall Survival (OS)
monthsNab-paclitaxel With Gemcitabine
Kaplan-Meier Estimate of Overall Survival (OS)9.2 (7.60 to 11.10)

Adverse events

Collected over TEAE that started: 1) From the date of first dose of study drug through 30 days after the last dose of study drug; collected from 20 Jan 2014 to 04 Aug 2016.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nab-paclitaxel and Gemcitabine—22/83 (26.5%)83/83 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventNab-paclitaxel and Gemcitabine
Upper gastrointestinal haemorrhageGastrointestinal disorders2/83
PyrexiaGeneral disorders2/83
Cerebral infarctionNervous system disorders2/83
AnaemiaBlood and lymphatic system disorders1/83
Febrile neutropeniaBlood and lymphatic system disorders1/83
LeukopeniaBlood and lymphatic system disorders1/83
NeutropeniaBlood and lymphatic system disorders1/83
Cardiac failureCardiac disorders1/83
Abdominal painGastrointestinal disorders1/83
Gastrointestinal obstructionGastrointestinal disorders1/83
Most frequent other events
Showing 10 of 57
Most frequent other events
EventNab-paclitaxel and Gemcitabine
LeukopeniaBlood and lymphatic system disorders56/83
NeutropeniaBlood and lymphatic system disorders55/83
Haemoglobin decreasedInvestigations50/83
ThrombocytopeniaBlood and lymphatic system disorders45/83
Decreased appetiteMetabolism and nutrition disorders43/83
NauseaGastrointestinal disorders41/83
FatigueGeneral disorders39/83
VomitingGastrointestinal disorders33/83
AlopeciaSkin and subcutaneous tissue disorders30/83
PyrexiaGeneral disorders29/83

Baseline characteristics

Intent to Treat (ITT) population includes all enrolled participants

Age, Continuous
Age, Continuous(years)Nab-paclitaxel and Gemcitabine
Mean56.2 ± 10.03
Sex: Female, Male
Sex: Female, Male(Participants)Nab-paclitaxel and Gemcitabine
Female25
Male58
Region of Enrollment
Region of Enrollment(participants)Nab-paclitaxel and Gemcitabine
China83
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(participants)Nab-paclitaxel and Gemcitabine
90-100% = normal activity, few symptoms of disease58
70-80% = normal activity, symptoms, cannot work25
50-60% = needs help and needs medical care0
<40% = disabled to severely disabled0
Number of Baseline Lesions (Target + Non-Target) by Independent Radiological Review
Number of Baseline Lesions (Target + Non-Target) by Independent Radiological Review(participants)Nab-paclitaxel and Gemcitabine
13
26
313
410
58
>543
08

Study locations

15 sites
  • Beijing Cancer Hospital
    Beijing, PR, 100142, China
  • 307 Hospital of Chinese PLA
    Beijing, 100039, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, 510060, China
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang, 100142, China
  • The First Affiliated Hospital of Medical School of Zhejiang University
    Hangzhou, Zhejiang, 100730, China
  • Zhejiang Cancer Hospital
    Hangzhou, 215006, China
  • Harbin Medical University Tumor Hospital
    Harbin, Heilongjiang, 150081, China
  • Jiangsu Province Hospital The First Hospital affiliated with Nanjing Medical University
    Nanjing, 210029, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, 300060, China
  • Xijing Hospital
    Xi'an, 710032, China
  • Henan Cancer Hospital
    Zhengzhou, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Jun 2015, 17 months.

Results were first posted in Nov 2016, 1 year 5 months after primary completion.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 17 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 20, 2013
StartActual
Dec 24, 2013
Primary completionActual
Jun 1, 2015
CompletionActual
Aug 3, 2016
Results first posted
Nov 22, 2016
Last update
Sep 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02017015
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 20, 2013
Start date
Dec 24, 2013
Primary completion
Jun 1, 2015
Completion
Aug 3, 2016
Results posted
Nov 22, 2016
Last update
Sep 26, 2017

Study contacts

Brian Lu, MD
study director · Celgene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion